PDCD1 and non-small cell lung carcinoma: Nivolumab is a fully human IgG4 monoclonal antibody against PD-1 and is approved for first-line treatment in melanoma, Hodgkin lymphoma, non-small cell lung cancer, head and neck cancer, and renal cell cancer [13].